Mizuho analyst Salim Syed raised the price target on Cytokinetics (NASDAQ: CYTK) to $100.00 (from $84.00) while maintaining a Outperform rating.

The analyst commented, "CYTK (OP, increasing PT to $100): ACACIA-HCM Ph3 top-line (expected 2Q26) remains a frequent investor inbound. We increased our PT to $100 (from $84), driven by extending aficamten IP to 2041 in our model (from 2039) and our nHCM PoS to 75% (from 65%). ACACIA-HCM (Ph3 nHCM) is setting up to be one of the largest fundamental clinical datasets we will get this year in biotech, in many ways reminiscent to how the inbox felt going into SEQUOIA-HCM (Ph3 oHCM). Not really getting pushback here from investors that the stock can trade back into the $90-100+ territory again, if successful here. We remain constructive going in."